Bractoppin |
カタログ番号GC62128 |
Bractoppin は、人間の BRCA1 タンデム (t) BRCT ドメイン (結合 IC50: 74 nM) によるリン酸化ペプチド認識の強力かつ選択的な薬物のような阻害剤です。 Bractoppin は BRCA1 の動員を DNA 切断に減少させ、損傷による G2 の停止とリコンビナーゼ RAD51 のアセンブリを抑制します。 Bractoppin は、DNA 損傷応答における BRCA1 tBRCT 依存のステップを優先的に阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2290527-07-8
Sample solution is provided at 25 µL, 10mM.
Bractoppin is a tandem BRCT (tandem BRCT, BRCA1) delivered by human breast and ovarian cancer suppressor protein (BRCA1) tBRCT domain recognizes a drug-like inhibitor of phosphopeptide that selectively inhibits nanomolar activity of substrate binding in vitro with an IC50 of 0.074 µM[1].
Bractoppin has nanomolar potency in displacing cognate BACH1 phosphopeptide substrate from the BRCA1 tBRCT. Its predicted binding mode to BRCA1 tBRCT reveals favorable hydrophobic interactions in the hydrophobic cavity, as well as a T-shaped, pi-pi stacking interaction with Phe1662, that together significantly contribute toward its activity. Indeed, substitution of the phenyl ring at R1 in Bractoppin with a 4-pyridyl group (CCBT2082) decreased activity by 5-fold by affecting the stacking interaction with Phe1662[1].
In cells, Bractoppin inhibits substrate recognition detected by FÖrster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51[1].
References:
[1]. Periasamy J, Kurdekar V, et,al. Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling. Cell Chem Biol. 2018 Jun 21;25(6):677-690.e12. doi: 10.1016/j.chembiol.2018.02.012. Epub 2018 Mar 29. PMID: 29606576; PMCID: PMC6015222.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *